TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07820085: A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

Sponsor: Portal Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 225 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,961,280

Rescue Site Savings

+$8,546,344

Unlock Full NCT07820085 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07820085 Rescue Dossier →